Kentucky Retirement Systems Cuts Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Kentucky Retirement Systems lowered its stake in shares of Catalent, Inc. (NYSE:CTLT) by 7.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,608 shares of the company’s stock after selling 1,030 shares during the quarter. Kentucky Retirement Systems’ holdings in Catalent were worth $764,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent during the second quarter worth $42,000. Sentry Investment Management LLC purchased a new stake in shares of Catalent during the third quarter worth $53,000. Longfellow Investment Management Co. LLC increased its position in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares during the period. GAMMA Investing LLC increased its position in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period. Finally, Intact Investment Management Inc. purchased a new stake in shares of Catalent during the third quarter worth $73,000.

Analyst Ratings Changes

Several research firms recently commented on CTLT. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a report on Thursday, November 14th. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $63.40.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,114 shares of company stock worth $305,931. Company insiders own 0.31% of the company’s stock.

Catalent Stock Performance

NYSE CTLT opened at $58.85 on Wednesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $61.20. The company has a market capitalization of $10.68 billion, a PE ratio of -26.04, a P/E/G ratio of 2.35 and a beta of 1.16. The company has a fifty day moving average of $59.80 and a two-hundred day moving average of $58.25.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the company earned ($0.10) EPS. The business’s revenue was up 4.2% on a year-over-year basis. As a group, analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.